531592
GENPHARMA
Start SIP
Invest Now
Start SIP in GENPHARMA
Performance
- Low
- ₹1
- High
- ₹1
- 52 Week Low
- ₹1
- 52 Week High
- ₹2
- Open Price₹1
- Previous Close₹1
- Volume3,586,443
- 50 DMA₹1.31
- 100 DMA₹1.47
- 200 DMA₹1.73
Investment Returns
- Over 1 Month + 5.51%
- Over 3 Month -10.67%
- Over 6 Month -32.66%
- Over 1 Year -41.48%
Smart Investing Starts Here Start SIP with Genpharmasec for Steady Growth!
Genpharmasec Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- -111.9
- PEG Ratio
- -
- Market Cap Cr
- 74
- P/B Ratio
- 1.1
- Average True Range
- 0.09
- EPS
- -
- Dividend Yield
- 0
- MACD Signal
- -0.04
- RSI
- 62.35
- MFI
- 78.71
Genpharmasec Financials
Genpharmasec Technicals
EMA & SMA
Current Price
₹1.34
+
0.1
(8.06%)
- Bearish Moving Average 5
- Bullish Moving Average 11
- 20 Day
- ₹1.22
- 50 Day
- ₹1.31
- 100 Day
- ₹1.47
- 200 Day
- ₹1.73
Resistance and Support
1.32
- R3 1.58
- R2 1.49
- R1 1.41
- S1 1.24
- S2 1.15
- S3 1.07
Genpharmasec Corporate Actions - Bonus, Splits, Dividends
| Date | Purpose | Remarks |
|---|---|---|
| 2026-02-09 | Quarterly Results | |
| 2025-11-06 | Quarterly Results | |
| 2025-09-02 | Others | Inter-alia, to consider 1. Fix the Day, Date, Time and approve Draft notice for the 33rd AGM of the Company. 2. The Directors Report for the year ended 31/03/2025. 3. Other business matters. issue of equity shares of Re. 1/- in the ratio of 1:1 @ premium of Re. 0.75/-. |
| 2025-08-07 | Quarterly Results | |
| 2025-05-21 | Audited Results |
Genpharmasec F&O
About Genpharmasec
- NSE Symbol
- GENPHARMA
- BSE Symbol
- 531592
- ISIN
- INE861N01036
Similar Stocks to Genpharmasec
Genpharmasec FAQs
Genpharmasec share price is ₹1 As on 12 February, 2026 | 00:46
The Market Cap of Genpharmasec is ₹74.2 Cr As on 12 February, 2026 | 00:46
The P/E ratio of Genpharmasec is -111.9 As on 12 February, 2026 | 00:46
The PB ratio of Genpharmasec is 1.1 As on 12 February, 2026 | 00:46
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.